EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment

Bongseo Choi, Jason Pe iD, Bo Yu, Dong-Hyun Kim iD

Cancers · 31.01.2023 · 15 (3) · 913

DOI: 10.3390/cancers15030913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 31.01.2023. Verfasst von Bongseo Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, National Cancer Institute and National Institute of Biomedical Imaging and Bioengineering.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rodent HCC rat models provide advantages for interventional oncology (IO) based immunotherapy research compared to other established larger animal models or mice models. Rapid and predictable tumor growth and affordable costs permit the formation of a compelling preclinical model investigating novel IO catheter-directed therapies and local ablation therapies. Among orthotopic HCC models, the N1-S1 orthotopic HCC model has been involved in many research cases. Suboptimal tumor induction rates and potential spontaneous regression during tumor implantation procedures discouraged the use of the N1-S1 HCC model in IO-based immunotherapies. Here, N1-S1 HCC models were generated with a subcapsular implantation of two different number of N1-S1 cells using a mini-laporatomy. Tumor growth assay and immunological profiles which can preclinically evaluate the therapeutic efficacy of IO-based immunotherapy, were characterized. Finally, an N1-S1 HCC rat model generated with the proposed procedure demonstrated a representative immune suppressive HCC tumor environment without self-tumor regression. The optimized syngeneic N1-S1 HCC rat models represent an essential tool for pre-clinical evaluation of new IO immunotherapies for the treatment of HCC.

Schlagwörter

Stichwörter der Autor:innen

cancer immunotherapyhepatocellular carcinoma (HCC)interventional oncologyrodent HCC animal model

Autor:innen und Institutionen

  • Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
  • Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL 60208, USA.
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
  • Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL 60607, USA.

ORCID-Profile: Jason Pe, Dong-Hyun Kim

Förderung

  • NCI NIH HHS
  • NIBIB NIH HHS
  • National Cancer Institute and National Institute of Biomedical Imaging and Bioengineering

Zitieren

APA

Choi, B., Pe, J., Yu, B., & Kim, D. H. (2023). Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. Cancers, 15(3), 913. https://doi.org/10.3390/cancers15030913

Vancouver

Choi B, Pe J, Yu B, Kim DH. Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. Cancers. 2023;15(3):913. doi:10.3390/cancers15030913

BibTeX
@article{Choi2023,
  author = {Choi, Bongseo and Pe, Jason and Yu, Bo and Kim, Dong-Hyun},
  title = {Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {913},
  doi = {10.3390/cancers15030913}
}
Kostenlos starten →